Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Briggs

Showing results (341-350 of 375) with videos related to

Pageof 38
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 15, 2022
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task ForceDon Husereau, Michael Drummond, Federico Augustovski, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 15, 2022
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic EvaluationsDon Husereau, Michael Drummond, Federico Augustovski, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|January 27, 2022
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluationsDon Husereau, Michael Drummond, Federico Augustovski, et al.
BMC Health Services Research|January 27, 2022
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluationsDon Husereau, Michael Drummond, Federico Augustovski, et al.
Health Policy OPEN|June 29, 2023
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: Updated reporting guidance for health economic evaluationsDon Husereau, Michael Drummond, Federico Augustovski, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|June 19, 2016
Development of the Galaxy Chronic Obstructive Pulmonary Disease (COPD) Model Using Data from ECLIPSE: Internal Validation of a Linked-Equations Cohort ModelAndrew H Briggs, Timothy Baker, Nancy A Risebrough, et al.
Plos Medicine|May 15, 2014
Methods for specifying the target difference in a randomised controlled trial: the Difference ELicitation in TriAls (DELTA) systematic reviewJenni Hislop, Temitope E Adewuyi, Luke D Vale, et al.
Health Technology Assessment (Winchester, England)|June 6, 2026
PERsonalised Medicine for Intensification of Treatment (PERMIT) in type 2 diabetes mellitus: a target trial emulation from routine dataDavid G Lugo-Palacios, Patrick Bidulka, Paul Charlton, et al.
Health Technology Assessment (Winchester, England)|May 9, 2014
Assessing methods to specify the target difference for a randomised controlled trial: DELTA (Difference ELicitation in TriAls) reviewJonathan A Cook, Jennifer Hislop, Temitope E Adewuyi, et al.
BMJ (Clinical Research Ed.)|May 8, 2024
Comparative effectiveness of second line oral antidiabetic treatments among people with type 2 diabetes mellitus: emulation of a target trial using routinely collected health dataPatrick Bidulka, David G Lugo-Palacios, Orlagh Carroll, et al.
Pageof 38

Showing results (341-350 of 375) with videos related to

Sort By:
Pageof 38
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 15, 2022
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task ForceDon Husereau, Michael Drummond, Federico Augustovski, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 15, 2022
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic EvaluationsDon Husereau, Michael Drummond, Federico Augustovski, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|January 27, 2022
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluationsDon Husereau, Michael Drummond, Federico Augustovski, et al.
BMC Health Services Research|January 27, 2022
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluationsDon Husereau, Michael Drummond, Federico Augustovski, et al.
Health Policy OPEN|June 29, 2023
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: Updated reporting guidance for health economic evaluationsDon Husereau, Michael Drummond, Federico Augustovski, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|June 19, 2016
Development of the Galaxy Chronic Obstructive Pulmonary Disease (COPD) Model Using Data from ECLIPSE: Internal Validation of a Linked-Equations Cohort ModelAndrew H Briggs, Timothy Baker, Nancy A Risebrough, et al.
Plos Medicine|May 15, 2014
Methods for specifying the target difference in a randomised controlled trial: the Difference ELicitation in TriAls (DELTA) systematic reviewJenni Hislop, Temitope E Adewuyi, Luke D Vale, et al.
Health Technology Assessment (Winchester, England)|June 6, 2026
PERsonalised Medicine for Intensification of Treatment (PERMIT) in type 2 diabetes mellitus: a target trial emulation from routine dataDavid G Lugo-Palacios, Patrick Bidulka, Paul Charlton, et al.
Health Technology Assessment (Winchester, England)|May 9, 2014
Assessing methods to specify the target difference for a randomised controlled trial: DELTA (Difference ELicitation in TriAls) reviewJonathan A Cook, Jennifer Hislop, Temitope E Adewuyi, et al.
BMJ (Clinical Research Ed.)|May 8, 2024
Comparative effectiveness of second line oral antidiabetic treatments among people with type 2 diabetes mellitus: emulation of a target trial using routinely collected health dataPatrick Bidulka, David G Lugo-Palacios, Orlagh Carroll, et al.
Pageof 38